The induction of classical metabolic risk factors for vascular disease by glucocorticoids (e.g. dyslipidemia, obesity) as well as the still unphysiological exposure under conventional glucocorticoid replacement therapy with subsequently increased IL-6 and the epinephrine deficiency itself may promote the increased CVR in AI [7]. This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.